100 related articles for article (PubMed ID: 20202515)
1. Plaque burden with composition? That is the next question.
Marso SP
J Am Coll Cardiol; 2010 Mar; 55(10):983-5. PubMed ID: 20202515
[No Abstract] [Full Text] [Related]
2. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial.
Hirohata A; Yamamoto K; Miyoshi T; Hatanaka K; Hirohata S; Yamawaki H; Komatsubara I; Murakami M; Hirose E; Sato S; Ohkawa K; Ishizawa M; Yamaji H; Kawamura H; Kusachi S; Murakami T; Hina K; Ohe T
J Am Coll Cardiol; 2010 Mar; 55(10):976-82. PubMed ID: 20202514
[TBL] [Abstract][Full Text] [Related]
3. Impact of angiotensin II receptor blocker therapy (olmesartan or valsartan) on coronary atherosclerotic plaque volume measured by intravascular ultrasound in patients with stable angina pectoris.
Ishii H; Kobayashi M; Kurebayashi N; Yoshikawa D; Suzuki S; Ichimiya S; Kanashiro M; Sone T; Tsuboi H; Amano T; Uetani T; Harada K; Marui N; Murohara T
Am J Cardiol; 2013 Aug; 112(3):363-8. PubMed ID: 23623047
[TBL] [Abstract][Full Text] [Related]
4. Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial.
Hirohata A; Yamamoto K; Miyoshi T; Hatanaka K; Hirohata S; Yamawaki H; Komatsubara I; Hirose E; Kobayashi Y; Ohkawa K; Ohara M; Takafuji H; Sano F; Toyama Y; Kusachi S; Ohe T; Ito H
Atherosclerosis; 2012 Jan; 220(1):134-8. PubMed ID: 22119063
[TBL] [Abstract][Full Text] [Related]
5. Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?
Consuegra-Sánchez L; Sanchis J; Núñez J; Cascón JD; Villegas M; Picó F
Rev Esp Cardiol (Engl Ed); 2012 Apr; 65(4):378-80. PubMed ID: 21840109
[No Abstract] [Full Text] [Related]
6. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
7. Porphyria cutanea tarda induced by olmesartan.
Mas-Vidal A; Coto-Segura P; García-Varona A; Santos-Juanes J
J Eur Acad Dermatol Venereol; 2010 Aug; 24(8):977-8. PubMed ID: 20015057
[No Abstract] [Full Text] [Related]
8. Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients.
Scholze J; Schaefer A; Kreutz R
Expert Opin Drug Saf; 2011 Mar; 10(2):185-96. PubMed ID: 21254872
[TBL] [Abstract][Full Text] [Related]
9. Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trial.
Miyoshi T; Hirohata A; Usui S; Yamamoto K; Murakami T; Komatsubara I; Kusachi S; Ohe T; Nakamura K; Ito H
Heart Vessels; 2014 Mar; 29(2):178-85. PubMed ID: 23563752
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation.
Radke PW; Figulla HR; Drexler H; Klues HG; Mügge A; Silber S; Daniel W; Schmeisser A; Reifart N; Motz W; Büttner HJ; Fischer D; Ortlepp JR; Schaefers K; Hoffmann R; Hanrath P;
Am Heart J; 2006 Oct; 152(4):761.e1-6. PubMed ID: 16996855
[TBL] [Abstract][Full Text] [Related]
11. Olmesartan for the prevention or delay of diabetic nephropathy: some considerations.
Catalá-López F; Martín-Serrano G; Maciá MA; Montero D
Rev Esp Cardiol (Engl Ed); 2012 Jul; 65(7):678-9; author reply 679-80. PubMed ID: 22608016
[No Abstract] [Full Text] [Related]
12. The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance.
Yoshida O; Hirayama H; Nanasato M; Watanabe T; Murohara T
Am Heart J; 2005 Jan; 149(1):e2. PubMed ID: 15660025
[TBL] [Abstract][Full Text] [Related]
13. [In diarrhea of unknown origin also think of olmesartan!].
Storr M
MMW Fortschr Med; 2015 Mar; 157(4):34. PubMed ID: 25743974
[No Abstract] [Full Text] [Related]
14. Effect of atherosclerotic regression on total luminal size of coronary arteries as determined by intravascular ultrasound.
Tardif JC; Grégoire J; L'Allier PL; Ibrahim R; Lavoie MA; LeMay M; Cohen E; Levesque S; Keller PF; Heinonen T; Guertin MC
Am J Cardiol; 2006 Jul; 98(1):23-7. PubMed ID: 16784914
[TBL] [Abstract][Full Text] [Related]
15. Severe angioedema associated with olmesartan.
Vasquez JL; Jaramillo JC; Fernandez C; Enriquez A; Mielgo R
Ann Allergy Asthma Immunol; 2011 Sep; 107(3):285. PubMed ID: 21875552
[No Abstract] [Full Text] [Related]
16. Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes.
Ingelfinger JR
N Engl J Med; 2011 Mar; 364(10):970-1. PubMed ID: 21388316
[No Abstract] [Full Text] [Related]
17. Impact of angiotensin II receptor blockers on the progression and regression of coronary atherosclerosis: an intravascular ultrasound study.
Waseda K; Ozaki Y; Takashima H; Ako J; Yasukawa T; Ismail TF; Hishida H; Ito T
Circ J; 2006 Sep; 70(9):1111-5. PubMed ID: 16936420
[TBL] [Abstract][Full Text] [Related]
18. [Multicenter trial of olmesartan. Main results].
Ageev FT; Svirida ON
Ter Arkh; 2011; 83(9):54-60. PubMed ID: 22145389
[TBL] [Abstract][Full Text] [Related]
19. Two amlodipine/ARB combinations for hypertension.
Med Lett Drugs Ther; 2007 Dec; 49(1276):101-2. PubMed ID: 18084152
[No Abstract] [Full Text] [Related]
20. Olmesartan-induced enteropathy.
Heerasing N; Hair C; Wallace S
Intern Med J; 2015 Jan; 45(1):117-8. PubMed ID: 25582943
[No Abstract] [Full Text] [Related]
[Next] [New Search]
